Zerocotin 1mg (Varenicline Salicylate)

Adult dose

1. Usual dose in adults Patients should set a quit date and start taking this medication 1 week before that date. Alternatively, they may start quitting between days 8 and 35 after starting this medication. This medication should be taken after meals with plenty of water. The recommended dosage is as follows: after dose titration over 1 week, take 1 mg twice daily. Days 1–3 0.5 mg once daily Days 4–7 0.5 mg twice daily Day 8 until the end of treatment 1 mg twice daily For patients who cannot tolerate the adverse reactions to this medication, the dose may be reduced temporarily or on an ongoing basis. The treatment period is 12 weeks. For patients who successfully quit smoking after the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medication is recommended to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, gradual smoking cessation while taking this medication should be considered. Smoking should be reduced by 50% from the level before treatment within the first 4 weeks after starting this medication, and by an additional 50% within the following 4 weeks. Smoking should continue to be reduced so that complete cessation is achieved by week 12. Continue this medication for an additional 12 weeks, for a total treatment period of 24 weeks. Patients who fail to quit smoking after the initial 12 weeks of treatment or resume smoking after treatment should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who fail to quit during the initial 12 weeks of treatment or resume smoking after treatment. 2. Patients with renal impairment No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 mL/min and ≤ 80 mL/min) to moderate (estimated creatinine clearance ≥ 30 mL/min and ≤ 50 mL/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 mL/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. 3. Elderly patients and patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. Because renal function is more likely to be reduced in elderly patients, care should be taken when selecting the dose, and monitoring renal function may be useful.

Child dose

Patients under 18 years of age: Use is not recommended because the safety and efficacy of this medication have not been established in children.

This medication is used to aid smoking cessation, and caution is needed regarding neuropsychiatric symptoms and suicidal tendencies. Symptoms affecting mental health, such as depression, anxiety, restlessness, aggressive behavior, hallucinations, and delusions may arise during treatment; if such symptoms occur, discontinue use immediately and consult a physician. This medication should not be administered to patients with hypersensitivity, and pregnant or breastfeeding women should use it cautiously. Common side effects during use include nausea, headache, insomnia, and unusual dreams, most of which are mild to moderate. Caution is needed when engaging in hazardous activities like driving or operating machinery, as drowsiness or dizziness may occur. Patients with cardiovascular disease should consult their physician thoroughly, as the use of this medication may worsen heart-related symptoms. Drug interactions are relatively low; however, abnormal and aggressive behavior has been reported with alcohol consumption, so it is advisable to avoid or limit alcohol intake. This medication is eliminated through the kidneys; therefore, dosage adjustment may be necessary for patients with impaired kidney function or the elderly. Overdose should be managed with standard treatment, and it is not recommended for children. Store this medication out of reach of children and keep it in its original container to prevent quality degradation.

• suicidal thoughts
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a sealed container to prevent exposure to air or moisture, keeping the storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage helps maintain the effectiveness of the medication.

Appearance

Light blue, bilaterally convex, rectangular film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)